Patients not taking their meds as prescribed cost the US $290 billion in increased medical costs.
And last week, Silicon Valley’s Proteus Biomedical announced the launch of their ‘digital health product’ in the UK, in collaboration with pharmacy chain Lloydspharmacy.
“The most important and basic thing we can monitor is the actual physical use of the medicine,” says Andrew Thompson of Proteus Biomedical.
These ‘sensor-enabled tablets’ are called Helius, and they come with ‘ingestible event markers.’ These can be taken with pills or incorporated directly into medicines by the manufacturers. The sensors are embedded in a placebo to be taken alongside the actual meds.
- The sensors are activated by stomach acid, and as Nature News explains, they’re powered much like potato batteries (where 2 different metals generate a current when inserted into the tuber).
- Each sensor – about the size of a grain of sand – contains a tiny amount of copper and magnesium. When you swallow one of these devices, you become the potato that creates a voltage. That then is used to power the device, which creates a signal.
- The digital signal can’t be detected except by an adhesive patch attached to your skin, like a bandage.
- It monitors things like heart rate, respiration, temperature, body posture, and even sleeping patterns – to show how you’re responding to the medication.
- These data are then relayed to your cellphone to be shared with whomever you like. Your doctor might decide to change dosages or medication based on that info.
Proteus Biomedical is developing and commercializing a range of digital health care products with others in the industry, such as Novartis, Medtronic, ON Semiconductor, and Kaiser Permanente. The company has already tested the system in hundreds of patients in many different therapeutic areas: tuberculosis, mental health, heart failure, hypertension, and diabetes.
Via Nature News, IEEE Spectrum.
Image: Proteus Biomedical